Japanese Encephalitis - Pipeline Review, H1 2012

Japanese Encephalitis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Japanese Encephalitis - Pipeline Review, H1 2012', provides an overview of the Japanese Encephalitis therapeutic pipeline. This report provides information on the therapeutic development for Japanese Encephalitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Japanese Encephalitis. 'Japanese Encephalitis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Japanese Encephalitis.
- A review of the Japanese Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Japanese Encephalitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Japanese Encephalitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Japanese Encephalitis pipeline depth and focus of Japanese Encephalitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Japanese Encephalitis Therapeutic Products under Development, Key Players in Japanese Encephalitis Therapeutics, Japanese Encephalitis Pipeline Overview, Japanese Encephalitis Pipeline, Japanese Encephalitis Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Japanese Encephalitis Overview
Therapeutics Development
An Overview of Pipeline Products for Japanese Encephalitis
Japanese Encephalitis Therapeutics under Development by Companies
Japanese Encephalitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Japanese Encephalitis Therapeutics – Products under Development by Companies
Japanese Encephalitis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Japanese Encephalitis Therapeutics Development
Sanofi-Aventis
Boryung Pharmaceutical Co., Ltd.
Panacea Biotec Limited
Sinovac Biotech Ltd.
Vaxine Pty Ltd
Japanese Encephalitis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
20% Diethyltoluamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Japanese Encephalitis SA 14-14-2 Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imojev - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Japanese Encephalitis Chimeric Virus Vaccine + MMR II Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vero Cell-derived Inactivated Japanese Encephalitis Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JEVAC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vero Cell Based Japanese Encephalitis Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JE/WNV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Japanese Encephalitis Therapeutics – Drug Profile Updates
Japanese Encephalitis Therapeutics – Discontinued Products
Japanese Encephalitis Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Japanese Encephalitis, H1 2012
Products under Development for Japanese Encephalitis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Sanofi-Aventis, H1 2012
Boryung Pharmaceutical Co., Ltd., H1 2012
Panacea Biotec Limited, H1 2012
Sinovac Biotech Ltd., H1 2012
Vaxine Pty Ltd, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Japanese Encephalitis Therapeutics – Drug Profile Updates
Japanese Encephalitis Therapeutics – Discontinued Products
Japanese Encephalitis Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Japanese Encephalitis, H1 2012
Products under Development for Japanese Encephalitis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012